endosomal escape patents, page-7

Janssen is clearly looking at a therapeutic outcomes. I mean that was the end goal right. They want to deliver their drugs to the target for commercial gain.

So, if they've confirmed EET, which seems generally accepted by now, then both parties may well want patent protection. Why would Janssen want to reveal anything re PYC until they'd locked it away or advanced it to a point they get maximum benefit? There is obviously merit in the thought.

Similarly with the notion that Janssen may be pushing PYC into the 'next deal' without really closing the last one, or making sure they'd stitched it up before closing the previous arrangement as part of "gaming" the PYC team. I hope PYC team manage to extract value rather than just chasing the next big deal without ever receiving a payday.